Association of plasma vitamin D concentration with prostate cancer risk: SELECT
Model | Vitamin D (nmol/L) | N (case) | N (cohort) | HR | 95% CI | P |
---|---|---|---|---|---|---|
Overall prostate cancer | ||||||
Model 1a | <37.5 | 199 | 464 | 1.00 | ||
37.5–<50 | 259 | 470 | 1.08 | 0.83–1.41 | 0.572 | |
50–<75 | 550 | 1,070 | 0.89 | 0.70–1.12 | 0.328 | |
≥75 | 723 | 1,199 | 0.98 | 0.78–1.24 | 0.897 | |
Model 2a,b | <37.5 | 183 | 426 | 1.00 | ||
37.5–<50 | 239 | 475 | 0.90 | 0.68–1.18 | 0.444 | |
50–<75 | 588 | 1,123 | 0.85 | 0.67–1.09 | 0.200 | |
≥75 | 721 | 1,179 | 0.96 | 0.75–1.23 | 0.763 | |
Model 3a,b,c | <44.1 | 308 | 639 | 1.00 | ||
44.1–<58.2 | 318 | 645 | 0.83 | 0.66–1.03 | 0.092 | |
58.2–<72.9 | 320 | 638 | 0.74 | 0.59–0.92 | 0.008 | |
72.9–<90.7 | 363 | 641 | 0.86 | 0.69–1.07 | 0.181 | |
≥90.7 | 422 | 640 | 0.98 | 0.78–1.21 | 0.823 | |
Gleason 2–6 prostate cancer | ||||||
Model 1a | <37.5 | 107 | 464 | 1.00 | ||
37.5–<50 | 157 | 470 | 1.20 | 0.87–1.65 | 0.269 | |
50–<75 | 309 | 1,070 | 0.90 | 0.67–1.20 | 0.454 | |
≥75 | 441 | 1,199 | 1.05 | 0.79–1.40 | 0.738 | |
Model 2a,b | <37.5 | 97 | 426 | 1.00 | ||
37.5–<50 | 137 | 475 | 0.94 | 0.67–1.32 | 0.732 | |
50–<75 | 345 | 1,123 | 0.89 | 0.66–1.21 | 0.467 | |
≥75 | 435 | 1,179 | 1.01 | 0.75–1.37 | 0.943 | |
Model 3a,b,c | <44.1 | 167 | 639 | 1.00 | ||
44.1–<58.2 | 190 | 645 | 0.87 | 0.66–1.14 | 0.302 | |
58.2–<72.9 | 190 | 638 | 0.76 | 0.58–1.00 | 0.048 | |
72.9–<90.7 | 210 | 641 | 0.86 | 0.66–1.13 | 0.276 | |
≥90.7 | 257 | 640 | 1.01 | 0.77–1.31 | 0.957 | |
Gleason 7–10 prostate cancer | ||||||
Model 1a | <37.5 | 67 | 464 | 1.00 | ||
37.5–<50 | 72 | 470 | 0.85 | 0.56–1.28 | 0.435 | |
50–<75 | 157 | 1,070 | 0.75 | 0.52–1.07 | 0.107 | |
≥75 | 206 | 1,199 | 0.86 | 0.60–1.22 | 0.402 | |
Model 2a,b | <37.5 | 60 | 426 | 1.00 | ||
37.5–<50 | 73 | 475 | 0.86 | 0.56–1.31 | 0.477 | |
50–<75 | 163 | 1,123 | 0.75 | 0.51–1.09 | 0.132 | |
≥75 | 206 | 1,179 | 0.91 | 0.63–1.33 | 0.642 | |
Model 3a,b,c | <44.1 | 104 | 639 | 1.00 | ||
44.1–<58.2 | 81 | 645 | 0.63 | 0.45–0.90 | 0.010 | |
58.2–<72.9 | 91 | 638 | 0.66 | 0.47–0.92 | 0.016 | |
72.9–<90.7 | 107 | 641 | 0.79 | 0.56–1.10 | 0.165 | |
≥90.7 | 119 | 640 | 0.88 | 0.63–1.22 | 0.436 | |
Gleason 8–10 prostate cancer | ||||||
Model 1a | <37.5 | 16 | 464 | 1.00 | ||
37.5–<50 | 14 | 470 | 0.71 | 0.32–1.58 | 0.406 | |
50–<75 | 27 | 1,070 | 0.41 | 0.20–0.83 | 0.013 | |
≥75 | 47 | 1,199 | 0.70 | 0.36–1.36 | 0.288 | |
Model 2a,b | <37.5 | 12 | 426 | 1.00 | ||
37.5–<50 | 15 | 475 | 0.96 | 0.41–2.25 | 0.926 | |
50–<75 | 29 | 1,123 | 0.55 | 0.25–1.20 | 0.131 | |
≥75 | 48 | 1,179 | 0.95 | 0.45–2.02 | 0.894 | |
Model 3a,b,c | <44.1 | 20 | 639 | 1.00 | ||
44.1–<58.2 | 20 | 645 | 0.68 | 0.34–1.34 | 0.267 | |
58.2–<72.9 | 13 | 638 | 0.36 | 0.16–0.78 | 0.010 | |
72.9–<90.7 | 27 | 641 | 0.85 | 0.44–1.65 | 0.630 | |
≥90.7 | 24 | 640 | 0.78 | 0.40–1.54 | 0.477 |